A Phase I Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects with Skin Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Tozuleristide (Primary)
Indications Basal cell cancer; Malignant melanoma; Skin cancer; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Blaze Bioscience

27 Oct 2015 According to a Blaze Bioscience media release, data from this study will be presented at the 2015 2nd Global Advances and Controversies in Skin Cancer (GAC-SC) Conference.
29 May 2015 Trial design presented at 51st Annual Meeting of the American Society of Clinical Oncology.
27 May 2015 According to a Blaze Bioscience media release, data from this study will be presented at the American Society of Surgical Oncology (ASCO) 2015 Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com